Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label Study to Investigate the Long-Term Safety and Efficacy of LP352 in the Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathy

NCT06908226 is registered in ClinicalTrials.gov with Longboard Pharmaceuticals as lead sponsor.

NCT NCT06908226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06908226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label Study to Investigate the Long-Term Safety and Efficacy of LP352 in the Treatment of Seizures in Children and Adults With Developmental and Epileptic Encephalopathy
Lead sponsor
Longboard Pharmaceuticals
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
February 12, 2025
Completion date
December 17, 2027
Enrollment
324 (estimated)
Sites
88

Conditions

As the registry lists them; a condition with its own page is linked.

developmental and epileptic encephalopathy